Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.22.2.2
License Agreements (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2015
USD ($)
shares
May 11, 2015
USD ($)
$ / shares
shares
Jun. 30, 2019
USD ($)
May 31, 2016
USD ($)
Mar. 31, 2015
USD ($)
Sep. 30, 2022
USD ($)
item
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
item
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
PD-L1                    
License Agreements                    
Non-Refundable milestone payment                   $ 4,000,000.0
NeuPharma, Inc                    
License Agreements                    
Payment of upfront licensing fees         $ 1,000,000.0          
NeuPharma, Inc | Additional sales milestone                    
License Agreements                    
Maximum potential milestone payments           $ 40,000,000.0   $ 40,000,000.0    
NeuPharma, Inc | Clinical and Development Milestone                    
License Agreements                    
Maximum potential milestone payments           40,000,000.0   40,000,000.0    
NeuPharma, Inc | Regulatory Approvals To Commercialize The Products                    
License Agreements                    
Maximum potential milestone payments           22,500,000   22,500,000    
Dana-Farber                    
License Agreements                    
Payment of upfront licensing fees         1,000,000.0          
Number of shares of common stock granted | shares 136,830 500,000                
Value of common stock shares issued $ 600,000 $ 32,500                
Sale price per share | $ / shares   $ 0.065                
Ownership percentage   5.00%                
Cash in exchange for common shares   $ 10,000,000                
Maintenance fee               50,000    
Dana-Farber | First commercial sale milestone                    
License Agreements                    
Maximum potential milestone payments           21,500,000   21,500,000    
Dana-Farber | Additional sales milestone                    
License Agreements                    
Maximum potential milestone payments           60,000,000.0   60,000,000.0    
Revenue recognition milestone payments           60,000,000.0   60,000,000.0    
Jubilant Biosys Limited                    
License Agreements                    
Payment of upfront licensing fees       $ 2,000,000.0            
Jubilant Biosys Limited | Additional sales milestone                    
License Agreements                    
Maximum potential milestone payments           89,000,000.0   89,000,000.0    
Jubilant Biosys Limited | Clinical and Development Milestone                    
License Agreements                    
Maximum potential milestone payments           89,000,000.0   89,000,000.0    
Jubilant Biosys Limited | Regulatory Approvals To Commercialize The Products                    
License Agreements                    
Maximum potential milestone payments           59,500,000   59,500,000    
Adimab LLC | PD-L1                    
License Agreements                    
Non-Refundable milestone payment                   $ 2,400,000
Adimab LLC | Clinical and Development Milestone                    
License Agreements                    
Maximum potential milestone payments           7,100,000   7,100,000    
Adimab LLC | Regulatory Approvals To Commercialize The Products                    
License Agreements                    
Maximum potential milestone payments           4,800,000   4,800,000    
Collaboration Agreement With TGTX                    
License Agreements                    
Proceeds from upfront fees     $ 1,000,000.0   $ 500,000          
Revenue recognition milestone revenue recognized           7,000 $ 1,000 54,000 $ 146,000  
Collaboration Agreement With TGTX | First commercial sale milestone | PD-L1                    
License Agreements                    
Revenue recognition milestone payments           27,600,000   27,600,000    
Collaboration Agreement With TGTX | First commercial sale milestone | PD-L1 GITR                    
License Agreements                    
Revenue recognition milestone payments           21,500,000   21,500,000    
Collaboration Agreement With TGTX | Clinical and Development Milestone | PD-L1 GITR                    
License Agreements                    
Revenue recognition milestone payments           7,000,000.0   7,000,000.0    
Collaboration Agreement With TGTX | Commercial Sales In Specified Territories | PD-L1                    
License Agreements                    
Revenue recognition milestone payments           19,200,000   19,200,000    
Collaboration Agreement With TGTX | Commercial Sales In Specified Territories | PD-L1 GITR                    
License Agreements                    
Revenue recognition milestone payments           14,500,000   14,500,000    
Collaboration Agreement With TGTX | Clinical Development and Regulatory Milestones | PD-L1                    
License Agreements                    
Revenue recognition milestone payments           8,400,000   8,400,000    
Sublicense Agreement with TGTX                    
License Agreements                    
Proceeds from upfront fees       $ 1,000,000.0            
Revenue recognition milestone revenue recognized           $ 41,000 $ 28,000 $ 64,000 $ 106,000  
Research and development cost           50.00%   50.00%    
Number of clinical development milestones | item           3   3    
Number of licensed products | item           2   2    
Sublicense Agreement with TGTX | Additional sales milestone                    
License Agreements                    
Revenue recognition milestone payments           $ 89,000,000.0   $ 89,000,000.0    
Sublicense Agreement with TGTX | Clinical and Development Milestone                    
License Agreements                    
Revenue recognition milestone payments           25,500,000   25,500,000    
Sublicense Agreement with TGTX | Five Regulatory Approvals And First Commercial Sales                    
License Agreements                    
Revenue recognition milestone payments           61,700,000   61,700,000    
Sublicense Agreement with TGTX | Clinical Development and Regulatory Milestones                    
License Agreements                    
Revenue recognition milestone payments           $ 87,200,000   $ 87,200,000